Apogee Therapeutics, Inc. Cash Flow Statement

1Y3Y5Y7Y10YAll
Download Data
Cash Flow Statement Dec2023 Dec2024
Operating Activities
Net Income -83.98M-182.15M
Depreciation and Depletion 0.20M
Share-based Compensation 6.10M23.33M
Gains from Investment Securities 2.30M10.84M
Cash from Operations -74.76M-171.20M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) 0.20M
Change in Working Capital
Change in Account Payables 1.61M-1.07M
Change in Accured Expenses 7.65M6.29M
Other Working Capital Changes 2.79M6.08M
Investing Activities
Capital Expenditures 0.21M1.15M
Change in Acquisitions & Divestments 30.00M350.14M
Cash from Investing Activities -273.91M-300.46M
Financing Activities
Other financing activities 6.10M23.33M
Cash from Financing Activities 315.39M495.11M
Additional items
Change in Cash -33.28M23.47M
Free Cash Flow -74.97M-172.35M
Net Cash Flow -33.28M23.45M